Re: [MedicaidforHDOT] Hyperbaric chambers obsolete?

[Guest guest]

It should be noted that this press release is for the purpose of promoting

stock sales and raising stock prices. Today, after the release, the stock

took a .21 jump. In addition, out of $1,528,000 in revenue in 2002, only

$68,000 was spent in Research and Development. It is common for companies

such as this to do press release to generate funds. This company had losses

of $947,000 in 2000, $748,000 in 2001 and $906,000 in 2002.

On the other hand, it is not uncommon for companies in developmental stages

to lose money. I do hope that this company can produce. This could be a

valuable asset in treatments. We can only wait and see.

Hartsoe

[MedicaidforHDOT] Hyperbaric chambers obsolete?

> From http://biz./prnews/040210/fltu012_1.html

>

> Hydron Technologies, Inc. Adds Clinical and Regulatory Consultants, Plans

> to Seek FDA Approval for Wound Care Oxygenation Technology

>

> Tuesday February 10, 11:15 am ET

>

> POMPANO BEACH, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Hydron

Technologies,

> Inc. (OTC Bulletin Board: HTEC - News) announced it has added expert

> clinical and regulatory consultants and will pursue approval from the FDA

> to allow the use of its oxygenation technology for a number of medical

> applications. Hydron has developed and received a U.S. patent for the

> method of oxygenating skin and tissue topically, using microbubbles of

pure

> oxygen suspended in fluid. This technology has important medical

> applications for improving medical treatments and quality of life for burn

> victims, chronic wound care, radiation induced injury, decubitus and

> pressure ulcers (bed sores), skin grafts and frostbite. Hydron has added

> two senior-level consultants to help structure the volumes of supporting

> materials and experimental results required by the FDA for approval of the

> new technology:

>

> Dr. Len Rosenberg -- Managing partner at eP2Consulting, Inc., a consulting

> firm focused on strategic clinical and regulatory solutions in the drug

and

> device development space for small to mid-size bio-pharmaceutical

companies.

>

> Dr. Judy Gordon -- Managing partner at ClinReg Consulting Services, Inc.,

a

> clinical and regulatory consulting group primarily focusing in device

> development. Dr. Gordon has successfully attained FDA approval for more

> than 10 original PMAs for Class III devices.

>

> According to Banakus, Hydron Technologies' CEO, " We believe the

> company has a significant innovation to offer to the medical community.

> Hydron's technology delivers the oxygen partial pressure of full

hyperbaric

> treatments to the surface of the skin in a simple, convenient liquid form,

> while also avoiding the expense of hyperbaric chambers. Ultimately this

> technology should allow for treatment of patients at home. "

>

> According to Dr. Rosenberg, " Within the FDA, it is not the use of oxygen

> that is regulated, rather, the FDA regulates the devices and means by

which

> the oxygen is delivered to tissue. The mechanism of oxygen's role in wound

> healing is well understood and there are a number of indications where

> oxygen is a significant adjunct to a wide variety of wound healing

> applications. Hydron's microbubble-laden fluids have been shown to

> penetrate tissue to depths in experimental models that should provide

> significant patient benefits. "

>

> Dr. Gordon stated, " I am pleased to be working on a project that has the

> potential to expand oxygen therapy for wounds, making it more convenient

> and accessible to a significantly broader range of patients. "

>

> Banakus added, " Hydron recently completed a private placement offering,

> raising $1.1 million, to accelerate its research and development program

> surrounding this technology. Now, with the addition of these new

> consultants and the development of a plan to approach the FDA, Hydron is

> furthering its shift into becoming a medical technology company. "

>

> Hydron Technologies, Inc. is expanding its research and development of

> products and medical applications associated with its proprietary tissue

> oxygenation technology. The Company also markets skin care products

through

> Hydron's direct-to-consumer catalog and on the Internet at www.hydron.com.

> Catalogs are available by calling 1-800-4-HYDRON (1-800-449-3766). Except

> for historical information, all of the expectations and assumptions

> contained in the foregoing are forward-looking statements involving risks

> and uncertainties. For additional information regarding the risks

> associated with the Company's business, refer to Hydron Technologies, Inc.

> reports filed with the SEC.

>

>

> ```````````````````````````````````````````````````````

>

>

> Freels

> 2948 Windfield Circle

> Tucker, GA 30084-6714

> 770/491-6776 (phone)

> 770-234-5757 (fax)

> mailto:dfreels@...

>

> http://www.freelanceforum.org/df

>

>

>

>

> _._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._.

> Join the International Hyperbaric Medical Association

http://www.hyperbaricmedicalassociation.org/forms/Friends_of_IHMA_Join.pdf

>

> EPSDT decisions http://healthlaw.org/pubs/200308.epsdtdocket.html

>

> Unrestricted downloads of 50+ pdf files on HBOT efficacy

medicaid/files/ ,

HDO-documentation/files/ and

http://www.drneubauerhbo.com/papers.htm

>

> Download your state EPSDT program

http://www.hcfa.gov/medicaid/stateplan/Map.asp by doing a search on the word

" ameliorate " . State Medicaid websites

http://www.medi-cal.ca.gov/RelSites_Oth_States.asp . Medicaid waiver

programs: http://www.geocities.com/HotSprings/Villa/1029/medicaid.html

>

> Find a hyperbaric clinic http://www.netnet.net/mums/hbolist.htm

>

> HBOT can save billions of dollars and millions of heartaches. Subscribe to

by sending a blank email to

mailto:medicaid-subscribe

>

> Unsubscribe? Click here mailto:medicaid-unsubscribe

..

>

[Guest guest]

:

Any solution that contains the oxygen levels available at 2.4 ATA @ 100%

could not exist at normobaric conditions for more than a few moments.

Also, Hunt showed the neovascularization is driven in the direction of

hypoxia, so increasing the oxygen to the surface of the wound may kill

bacteria, but it will inhibit neovascularization of that wound.

This is all marketing hype.

KP Stoller, MD, FAAP

Assistant Clinical Prof, UNM HSC Dept Pediatrics

Simply Hyperbarics

www.simplyhyperbarics.com

> From http://biz./prnews/040210/fltu012_1.html

>

> Hydron Technologies, Inc. Adds Clinical and Regulatory Consultants,

> Plans to Seek FDA Approval for Wound Care Oxygenation Technology

>

> Tuesday February 10, 11:15 am ET

>

> POMPANO BEACH, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Hydron

> Technologies, Inc. (OTC Bulletin Board: HTEC - News) announced it has

> added expert clinical and regulatory consultants and will pursue

> approval from the FDA to allow the use of its oxygenation technology for

> a number of medical applications. Hydron has developed and received a

> U.S. patent for the method of oxygenating skin and tissue topically,

> using microbubbles of pure oxygen suspended in fluid. This technology

> has important medical

> applications for improving medical treatments and quality of life for

> burn victims, chronic wound care, radiation induced injury, decubitus

> and pressure ulcers (bed sores), skin grafts and frostbite. Hydron has

> added two senior-level consultants to help structure the volumes of

> supporting materials and experimental results required by the FDA for

> approval of the new technology:

>

> Dr. Len Rosenberg -- Managing partner at eP2Consulting, Inc., a

> consulting firm focused on strategic clinical and regulatory solutions

> in the drug and device development space for small to mid-size

> bio-pharmaceutical companies.

>

> Dr. Judy Gordon -- Managing partner at ClinReg Consulting Services,

> Inc., a clinical and regulatory consulting group primarily focusing in

> device development. Dr. Gordon has successfully attained FDA approval

> for more than 10 original PMAs for Class III devices.

>

> According to Banakus, Hydron Technologies' CEO, " We believe the

> company has a significant innovation to offer to the medical community.

> Hydron's technology delivers the oxygen partial pressure of full

> hyperbaric treatments to the surface of the skin in a simple, convenient

> liquid form, while also avoiding the expense of hyperbaric chambers.

> Ultimately this technology should allow for treatment of patients at

> home. "

>

> According to Dr. Rosenberg, " Within the FDA, it is not the use of oxygen

> that is regulated, rather, the FDA regulates the devices and means by

> which the oxygen is delivered to tissue. The mechanism of oxygen's role

> in wound healing is well understood and there are a number of

> indications where oxygen is a significant adjunct to a wide variety of

> wound healing applications. Hydron's microbubble-laden fluids have been

> shown to penetrate tissue to depths in experimental models that should

> provide significant patient benefits. "

>

> Dr. Gordon stated, " I am pleased to be working on a project that has the

> potential to expand oxygen therapy for wounds, making it more convenient

> and accessible to a significantly broader range of patients. "

>

> Banakus added, " Hydron recently completed a private placement offering,

> raising $1.1 million, to accelerate its research and development program

> surrounding this technology. Now, with the addition of these new

> consultants and the development of a plan to approach the FDA, Hydron is

> furthering its shift into becoming a medical technology company. "

>

> Hydron Technologies, Inc. is expanding its research and development of

> products and medical applications associated with its proprietary tissue

> oxygenation technology. The Company also markets skin care products

> through Hydron's direct-to-consumer catalog and on the Internet at

> www.hydron.com. Catalogs are available by calling 1-800-4-HYDRON

> (1-800-449-3766). Except for historical information, all of the

> expectations and assumptions contained in the foregoing are

> forward-looking statements involving risks and uncertainties. For

> additional information regarding the risks

> associated with the Company's business, refer to Hydron Technologies,

> Inc. reports filed with the SEC.

>

>

> ```````````````````````````````````````````````````````

>

>

> Freels

> 2948 Windfield Circle

> Tucker, GA 30084-6714

> 770/491-6776 (phone)

> 770-234-5757 (fax)

> mailto:dfreels@...

>

> http://www.freelanceforum.org/df

>

>

>

>

> _._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._._.

> Join the International Hyperbaric Medical Association

> http://www.hyperbaricmedicalassociation.org/forms/Friends_of_IHMA_Join.pdf

>

> EPSDT decisions http://healthlaw.org/pubs/200308.epsdtdocket.html

>

> Unrestricted downloads of 50+ pdf files on HBOT efficacy

> medicaid/files/ ,

> HDO-documentation/files/ and

> http://www.drneubauerhbo.com/papers.htm

>

> Download your state EPSDT program

> http://www.hcfa.gov/medicaid/stateplan/Map.asp by doing a search on the

> word " ameliorate " . State Medicaid websites

> http://www.medi-cal.ca.gov/RelSites_Oth_States.asp . Medicaid waiver

> programs: http://www.geocities.com/HotSprings/Villa/1029/medicaid.html

>

> Find a hyperbaric clinic http://www.netnet.net/mums/hbolist.htm

>

> HBOT can save billions of dollars and millions of heartaches. Subscribe

> to by sending a blank email to

> mailto:medicaid-subscribe

>

> Unsubscribe? Click here

> mailto:medicaid-unsubscribe .

> Links

>

>

>

>

[Guest guest]

At 02:40 PM 2/10/2004, you wrote:

RE: $68,000 was spent in Research and Development.

Note that once R & D reaches certain stages of viability, it becomes asset

amortized over an extended period of time (up to 20 years, I believe) , and

not an expense. Therefore, you might have to dig to find accurate info. on

R & D. The difference may be the accounting practices required, rather than

changes in efforts.

Best REgards,

Ed

Ed Nemeth

President, CEO

Spectrum Events

444 North Third Street, Suite 304

Sacramento, CA 95814

916-856-7044 x 339

916-856-7040 (fax)